SCHEMBL6045663

SCHEMBL6045663

Cc1ccc(C2(Nc3ccccc3)CCN(Cc3ccccc3)CC2)nc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.47
NPFFR1 Q9GZQ6 2/20 0.45
NPFFR2 Q9Y5X5 2/20 0.45
CYP3A4 P08684 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SIGMAR1 Q99720 4/20 0.41
FAAH O00519 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
OPRL1 P41146 1/20 0.40
ACHE P22303 1/20 0.40
BACE1 P56817 1/20 0.40
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
CYP2C9 P11712 1/20 0.39
TSHR P16473 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
HIF1A Q16665 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6045724 0.82 NPFFR1 (0.44) LMNAPOLBNPFFR1NPFFR2CYP3A4
SCHEMBL6045466 0.81 NPFFR1 (0.46) LMNAPOLBNPFFR1NPFFR2CYP3A4
SCHEMBL30122291 0.76 OPRL1 (0.58) POLBNPFFR1NPFFR2CYP3A4HSD17B10
SCHEMBL6045515 0.75 NPFFR1 (0.46) POLBNPFFR1NPFFR2CYP3A4HSD17B10
SCHEMBL6045725 0.74 NPFFR1 (0.43) POLBNPFFR1NPFFR2CYP3A4HSD17B10
SCHEMBL6045533 0.74 CYP3A4 (0.45) LMNAPOLBNPFFR1NPFFR2CYP3A4
SCHEMBL9372890 0.74 NPFFR1 (0.45) POLBNPFFR1NPFFR2CYP3A4HSD17B10
SCHEMBL6045459 0.74 NPFFR1 (0.45) POLBNPFFR1NPFFR2CYP3A4HSD17B10
SCHEMBL7468609 0.73 CYP2D6 (0.45) LMNAPOLBCYP3A4OPRL1ALDH1A1
SCHEMBL27296558 0.72 NPFFR1 (0.46) POLBNPFFR1NPFFR2CYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060252797-A1 Receptor regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-11-09 US disclosed
EP-1559428-A1 RECEPTOR REGULATOR Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252797-A1 Receptor regulator NMUR1, NMUR2, NMBR LMNA 1044/4885POLB 4597/4885NPFFR1 39/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.